BioSpace News Archive

Veru Inc. announced financial results for its fiscal 2023 third quarter and provided a business update.

Immunocore Holdings plc announced its financial results for the second quarter ended June 30, 2023, and provided a business update.

Gain Therapeutics, Inc., a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.

Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2023, and provided operational updates.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its second quarter operating and financial results and reviewed recent business highlights.

Regeneron Pharmaceuticals, Inc. announced positive, two-year, topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, reported financial results for the second quarter ended June 30, 2023.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).

Soligenix, Inc. announced today that patient enrollment has been opened for the investigator-initiated study (IIS) at the University of Pennsylvania, supported by a $2.6 million Orphan Products Development grant award by the U.S. Food and Drug Administration (FDA).